Tags: APFN | US | Merck | Vytorin | Study

Merck's Vytorin Cuts Heart Attack Risk in Kidney Patients

Monday, 22 Nov 2010 10:07 AM

Drugmaker Merck says a new study shows that its cholesterol drug Vytorin helps reduce the risk of heart attack, stroke and the need for heart surgeries in some chronic kidney patients by 16 percent.

The Oxford University study released on Saturday looked at more than 9,000 patients who had advanced or end-stage chronic kidney disease. Merck says that based on the study results, it will seek approval to use the drug for patients with chronic kidney disease.

Merck & Co., based in Whitehouse Station, N.J., says the result is significant because kidney patients have a high risk of vascular disease. It also helps Merck, because the company has been dealing with increased competition.

There also has been controversy about whether Vytorin is beneficial in some uses compared with other drugs.

© Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

 
1Like our page
2Share
Companies
Drugmaker Merck says a new study shows that its cholesterol drug Vytorin helps reduce the risk of heart attack, stroke and the need for heart surgeries in some chronic kidney patients by 16 percent.The Oxford University study released on Saturday looked at more than 9,000...
APFN,US,Merck,Vytorin,Study
130
2010-07-22
Monday, 22 Nov 2010 10:07 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved